| First Author | Kim DK | Year | 2013 |
| Journal | Diabetes | Volume | 62 |
| Issue | 9 | Pages | 3093-102 |
| PubMed ID | 23775767 | Mgi Jnum | J:208952 |
| Mgi Id | MGI:5565427 | Doi | 10.2337/db12-0946 |
| Citation | Kim DK, et al. (2013) Inverse agonist of nuclear receptor ERRgamma mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes 62(9):3093-102 |
| abstractText | Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder with diverse pathological manifestations and is often associated with abnormal regulation of hepatic glucose production. Many nuclear receptors known to control the hepatic gluconeogenic program are potential targets for the treatment of T2DM and its complications. Nevertheless, the therapeutic potential of the estrogen-related receptor gamma (ERRgamma) in T2DM remains unknown. In this study, we show that the nuclear receptor ERRgamma is a major contributor to hyperglycemia under diabetic conditions by controlling hepatic glucose production. Hepatic ERRgamma expression induced by fasting and diabetic conditions resulted in elevated levels of gluconeogenic gene expression and blood glucose in wild-type mice. Conversely, ablation of hepatic ERRgamma gene expression reduced the expression of gluconeogenic genes and normalized blood glucose levels in mouse models of T2DM: db/db and diet-induced obesity (DIO) mice. In addition, a hyperinsulinemic-euglycemic clamp study and long-term studies of the antidiabetic effects of GSK5182, the ERRgamma-specific inverse agonist, in db/db and DIO mice demonstrated that GSK5182 normalizes hyperglycemia mainly through inhibition of hepatic glucose production. Our findings suggest that the ability of GSK5182 to control hepatic glucose production can be used as a novel therapeutic approach for the treatment of T2DM. |
